# Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

Study · id `cardio:ct-nct01135017` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01135017](<https://clinicaltrials.gov/study/NCT01135017>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01135017

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.

## Technical summary

Registry record NCT01135017. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2013-04-01.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Primary completion: 2012-02 (actual) (ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Completion: 2012-02 (actual) (ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Results first posted: 2013-04-01 (ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01135017, source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01135017-2013-04-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
- Acronym: HESTIA
- Condition: Atrial Fibrillation
- Intervention (Drug): Dronedarone
- Intervention (Drug): Placebo (for Dronedarone)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: e233a2f06f7392f1ab72fedb94056ad94924a135136318d5b93f6ad742fddf09
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
